Skip to main content

Table 1 Patient characteristics ( N =146)

From: Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy

Patient characteristics at baseline Values at baseline Patient characteristics at follow-up Values at follow-up
Age (years), median (IQR) (N =146) 68 (62 to 74) Age (years), median (IQR) (N =146) 71 (65 to 77)
Baseline PSA (ng/mL), median (IQR) (N =146) 72 (20 to 187) Follow-up PSA (ng/mL), median (IQR) (N =146) 23 (2.6 to 89)
Baseline BSI (N =146)   Follow-up BSI (N =146)  
BSI =0 (M0), N (%) 84 (57%) BSI =0 (M0), N (%) 55 (37%)
BSI >0 (M1), N (%) 62 (43%) BSI >0 (M1), N (%) 91 (63%)
BSI >0, median (IQR) 1.5 (0.2 to 4.2) BSI >0, median (IQR) 1.7 (0.3 to 4.9)
Clinical T stage (N =131)   BSI change from baseline to follow-up (N =146)  
T1, N (%) 9 (7%)   
T2, N (%) 21 (16%)   
T3, N (%) 85 (65%) BSI increased:  
T4, N (%) 16 (12%) High BSI change, N (%) 67 (46%)
Gleason score (N =135)   BSI unchanged/decreased:  
5, N (%) 1 (0.7%) Low BSI change, N (%) 79 (54%)
6, N (%) 6 (4.3%)   
7, N (%) 48 (36%)   
8, N (%) 36 (26%)   
9, N (%) 39 (29%)   
10, N (%) 5 (4%)   
  1. N, number of patients; IQR, interquartile range; BSI, Bone Scan Index;PSA, prostate-specific antigen; M0, absence of metastasis; M1, presence of bone metastasis.